These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 14650470

  • 1. Scleroderma: a treatable disease.
    Korn JH.
    Cleve Clin J Med; 2003 Nov; 70(11):954, 956, 958 passim. PubMed ID: 14650470
    [Abstract] [Full Text] [Related]

  • 2. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
    Furuya Y, Kuwana M.
    J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
    [Abstract] [Full Text] [Related]

  • 3. [Systemic sclerosis: paths into the future].
    Guillevin L.
    Presse Med; 2006 Dec; 35(12 Pt 2):1892-3. PubMed ID: 17159714
    [No Abstract] [Full Text] [Related]

  • 4. Targeting mediators of vascular injury in scleroderma.
    Schachna L, Wigley FM.
    Curr Opin Rheumatol; 2002 Nov; 14(6):686-93. PubMed ID: 12410092
    [Abstract] [Full Text] [Related]

  • 5. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
    Nishibu A, Sakai E, Oyama N, Yamamoto T.
    Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581
    [Abstract] [Full Text] [Related]

  • 6. [Long-term therapy with endothelin-1 antagonist for pulmonary hypertension secondary to systemic sclerosis].
    Shalev L, Langevitz P, Zandman-Goddard G.
    Harefuah; 2008 Apr; 147(4):287-9, 376. PubMed ID: 18686806
    [Abstract] [Full Text] [Related]

  • 7. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP, Humbert M, Rubin L, Black CM.
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [Abstract] [Full Text] [Related]

  • 8. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
    Ahmadi-Simab K, Hellmich B, Gross WL.
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
    [Abstract] [Full Text] [Related]

  • 9. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.
    Jain M, Varga J.
    Expert Opin Pharmacother; 2006 Aug; 7(11):1487-501. PubMed ID: 16859432
    [Abstract] [Full Text] [Related]

  • 10. Bosentan in systemic sclerosis.
    Heresi GA, Minai OA.
    Drugs Today (Barc); 2008 Jun; 44(6):415-28. PubMed ID: 18596996
    [Abstract] [Full Text] [Related]

  • 11. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
    Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C.
    Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
    [Abstract] [Full Text] [Related]

  • 12. Resolution of severe digital ulceration during a course of Bosentan therapy.
    Snyder MJ, Jacobs MR, Grau RG, Wilkes DS, Knox KS.
    Ann Intern Med; 2005 May 03; 142(9):802-3. PubMed ID: 15867420
    [No Abstract] [Full Text] [Related]

  • 13. Digital ulcers: overt vascular disease in systemic sclerosis.
    Steen V, Denton CP, Pope JE, Matucci-Cerinic M.
    Rheumatology (Oxford); 2009 Jun 03; 48 Suppl 3():iii19-24. PubMed ID: 19487218
    [Abstract] [Full Text] [Related]

  • 14. Targeted therapy for systemic sclerosis.
    Steen V.
    Autoimmun Rev; 2006 Feb 03; 5(2):122-4. PubMed ID: 16431341
    [Abstract] [Full Text] [Related]

  • 15. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV.
    Eur J Clin Invest; 2006 Sep 03; 36 Suppl 3():10-5. PubMed ID: 16919005
    [Abstract] [Full Text] [Related]

  • 16. [Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
    Musch A.
    Med Monatsschr Pharm; 2006 Jul 03; 29(7):242-5. PubMed ID: 16866076
    [Abstract] [Full Text] [Related]

  • 17. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.
    Rheumatology (Oxford); 2010 Mar 03; 49(3):490-500. PubMed ID: 20015974
    [Abstract] [Full Text] [Related]

  • 18. Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD.
    Liefeldt L, van Giersbergen PL, Dingemanse J, Rudolph B, Walde T, Budde K, Neumayer HH, Hocher B.
    Am J Kidney Dis; 2004 May 03; 43(5):923-6. PubMed ID: 15112184
    [Abstract] [Full Text] [Related]

  • 19. New therapeutic strategies for systemic sclerosis--a critical analysis of the literature.
    Zandman-Goddard G, Tweezer-Zaks N, Shoenfeld Y.
    Clin Dev Immunol; 2005 Sep 03; 12(3):165-73. PubMed ID: 16295521
    [Abstract] [Full Text] [Related]

  • 20. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ.
    Lancet; 2001 Oct 06; 358(9288):1119-23. PubMed ID: 11597664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.